Pharma's Market
SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- Gold Retreats from Record High as Dollar Rebounds
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Chinese Overcapacity is Worsening, EU Chamber Warns
- Fannie Mae to Tighten Lending Standards: Report
- Wal-Mart Price Pressure Hurts China Workers: Report
- China Unveils Carbon Target Ahead of Copenhagen
- Hyundai-Kia Targets Rapid China Growth in 2010
- Great Britain, No Longer That Great: Investor
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Struggles to Ease Debt Fears; Investors Rattled
- Japanese Stocks Likely to Fall Broadly on Dubai Worries
- US Dollar Falls to 14-Year Low Against the Yen
- US Companies Already Moving on Curbing Emissions
- Fannie Mae to Tighten Lending Standards: Report
- Investing in Good Karma – and Making a Profit
- Retailers Should Believe in Christmas Miracles
- Bankruptcies Jump, Hitting Highest Level in Four Years
- Steepest Black Friday Discounts, Revealed
PHARMA'S MARKET VIDEO
RSS FEED
Text Size 
Reporter
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Amgen released more encouraging data on the late-stage developmental drug Prolia for bone loss in cancer patients. Onyx Pharmaceuticals unveiled positive breast cancer test results with its drug Nexavar. OSI Pharmaceuticals presented promising numbers in a couple of lung cancer patient subgroups with its pill Tarceva. And on the deal side BioCryst Pharmaceuticals announced the government is giving the company another $77 million to finish testing on its experimental, injectable flu-fighter peramivir. AstraZeneca said it's teaming up with the previously left-for-dead Nektar Therapeutics. And even Dell's deal for Perot Systems is moving some healthcare-related stocks.
Leerink Swann, which specializes in healthcare sector coverage, says about half of PER's revenue comes from healthcare information technology (IT).
I had no idea, but LS says Perot is the biggest provider of outsourced services to American hospitals, contracts with around 30,000 docs and has a big international business as well.
In a research note analyst George Hill is telling clients that Perot could take its eye off the ball during the integration. In the meantime, Hill says competitors including Cerner Corp., Computer Programs & Systems, Inc. and Eclipsys Corp. could steal market share. Shares of CERN and CPSI hit new intra-day highs.
The Dell/Perot deal is grabbing the M & A headlines today, but the partnership deal between AZN and NKTR is big, too. When Pfizer unceremoniously dumped its inhalable insulin Exubera because it wasn't selling very well, the partner on the unsuccessful product, Nektar Therapeutics, was left out in the cold. But today NKTR is rising from the ashes. The agreement with AZN on a Nektar drug for constipation caused by pain meds is worth nearly $1.5 billion over time, according to an estimate by Brean Murray Carret & Co. analyst Jonathan Aschoff. In intra-day trading, NKTR shares are also at a new high.
Aschoff says the American market to treat it is worth $1.3 billion and the worldwide potential is more than twice that amount. Chronic constipation in patients who take opiate painkillers is a big problem. I wouldn't know. Hope I never do.
Disclosures: BMC makes a market in NKTR and wants to bank the company.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes